TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00470405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 75-100 mg/m2 iv infusion Approximately 2 hours beginning approximately 30 minutes after the end of ALIMTA infusion on Day 1 of a 14-days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: a novel antifolate with multiple targets.
Study: NCT01558323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Description: Participants will receive a single oral dose of LCQ908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Description: Participants will receive a single oral dose of LCQ908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Description: Participants will receive a single oral dose of LCQ908
Study: NCT02367105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Daily testosterone gel applied once daily in the morning to intact skin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle Therapy
Description: Weekly behavioral diet to induce \~10% weight loss in combination with supervised aerobic and exercise training three times a week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Therapy
Description: Weekly behavioral diet to induce \~10% weight loss in combination with supervised aerobic and exercise training three times a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel for testosterone
Study: NCT00974181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)
Description: Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (10 µg Paclitaxel)
Study: NCT04174365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Oral tablet; take once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally daily for up to Week 8.
Study: NCT03084315

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: E-Cig Zero Nicotine
Description: E-Cig Zero Nicotine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-Cig 24mg Nicotine
Description: E-Cig 24mg Nicotine
Study: NCT01487239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GDC-0980
Description: 100 uCi of \[14C\]-GDC-0980 in total dose of 10 mg GDC-0980
Study: NCT02308371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Pulse Pressure Variation
Description: Based on standard of care, the physician will give fluid as needed based on standard clinical data (heart rate, central venous pressure if available, blood pressure, urine output, physical exam, lactate level) and pulse pressure variation. PPV should be elevated consistently greater than 15 minutes before giving fluid without other symptoms of patient instability (low blood pressure, elevated lactate, tachycardia). Pulse pressure variation will be followed for 48 hours.
Study: NCT01046357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7687
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose
Study: NCT01644760

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasounds with controlled breathing
Description: The patient will have cardiac, abdominal and thoracic ultrasounds with controlled and monitored inspiratory effort. This gesture takes about 40 minutes.
Study: NCT00935064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Pill, 300 mg, once daily, for 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo orally one tablet once a day for 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally one tablet once a day for 6 weeks.
Study: NCT03394417

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: StrataXRT
Description: randomized patient allocated to this group will receive StrataXRT for application during the treatment and 4 weeks further after the treatment ends.
Study: NCT02565199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS over Premotor Cortex (Contralateral Hemisphere)
Description: * Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: MagStim Super Rapid 2 Transcranial Magnetic Stimulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS over Premotor Cortex (Ipsilateral Hemisphere)
Description: * Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS (Control 1)
Description: * Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 400 milliseconds after the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS (Control 2)
Description: * Location of rTMS: somatosensory cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS (Control 3)
Description: * Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator with Sham Coil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Training
Description: During motor training, participants will quickly extend their hand at a pace of one extension every 5 seconds (0.2Hz) in response to an auditory cue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Training
Description: During motor training, participants will quickly extend their hand at a pace of one extension every 5 seconds (0.2Hz) in response to an auditory cue.
Study: NCT03274362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headspace Mindfulness App
Description: Participants will be given instructions on how to download Headspace on an electronic device and will be provided a free 3-month access code. The app contains a series of ten step-wise 10-minute video sessions that guide the user through mindfulness training. Upon completion of these sessions, additional content will be accessible, including sessions on health (depression, self-esteem, anxiety, sleep, and pregnancy), relationships (kindness, generosity, relationships, change, appreciation, and acceptance) and performance (creativity, focus, happiness, and balance). The frequency and duration of usage will be in accordance to the instructions of the app.
Study: NCT00513357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 20 mg by mouth daily for 4 Weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule by mouth daily for 4 Weeks
Study: NCT03606694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydromyricetin
Description: The intervention wiil be 300 mg, two times per day before break-fast and dinner during 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The intervention wiil be 850 mg, two times per day before break-fast and dinner during 12 weeks.
Study: NCT01147003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational new drug, company code: BGG492

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational new drug, company code: BGG492
Study: NCT04967859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% gentamicin
Description: Patient using 0.1% gentamicin ointment at the exit site of the hemodialysis catheter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients using placebo ointment at the exit site of the hemodialysis catheter
Study: NCT04212832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.5 ml/kg %0.25 bupivacaine

Intervention type: OTHER
Group type: OTHER
Intervention: Standard pain
Description: Standard pain follow up and monitorization
Study: NCT00653978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP plus one biliary stent
Description: ERCP ＋ one biliary stent insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP plus two biliary stents
Description: ERCP ＋ two biliary stents insertion
Study: NCT01724684

Intervention type: OTHER
Group type: OTHER
Intervention: Telehealth program

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study: NCT02533297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing clinical skills conditions
Study: NCT03353181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic scissors
Description: Application of endoscopic cutting technique following endoscopic nasobiliary drainage in the treatment of malignant hilar biliary strictures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary stent
Description: Standard placement of biliary stent
Study: NCT01417858

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: YAG laser peripheral iridotomy
Description: 1 drop 30 minutes before yag laser iridotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: YAG laser peripheral iridotomy
Description: 1 drop 30 minutes before yag laser iridotomy
Study: NCT00560911

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: educational program for the self-management of OAC
Description: Patients in the self-management group participated in 4 consecutive weekly instruction sessions of 90 to 120 minutes each, in groups of 3 to 6 patients.~After participation in the structured programme, the patients were encouraged to control their INR values by self-monitoring once a week and to adjust their anticoagulant dosage accordingly.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 1 hour education - afterwards physician leaded OAC control
Description: Patients in the routine control group participated a single 90-minute session~During the whole study period, they were advised with regard to changes in the anticoagulant dosage by their usual attending physicians, either in general practice or at a hospital-based specialised anticoagulation clinic.
Study: NCT00550264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automatic notification of readmissions
Description: The experimental group physicians will receive automatic e-mail notification when a patient is readmitted, including contact information for the readmitting team.
Study: NCT03062397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JPI-289 Low-dose
Description: JPI-289 Low dose will be intravenously administered during 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JPI-289 High-dose
Description: JPI-289 High dose will be intravenously administered during 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same dosage of JPI-289 Low and Hogh dose will be intravenously administered during 24 hours
Study: NCT02503371

Intervention type: OTHER
Intervention: Blood coagulation anyalsis by Thromboelastogram
Description: Two blood tests will be taken during routine tests from all parturient s undergoing IVF treatment before starting gonadotropins treatment (the first few days of menstruation) and at the height of hormone therapy prior to egg retrieval Coagulation parameters will be measured by the use of Thromboelastogram
Study: NCT03001466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urea-loaded nanoparticles eye drops
Description: one drop five times a day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Balance Salt Solution eye drops
Description: one drop five times a day for 8 weeks
Study: NCT01758159

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron supplementation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CFR
Description: Complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CFR
Description: Complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
Study: NCT00974181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)
Description: Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (30 µg Paclitaxel)
Study: NCT03268109

Intervention type: OTHER
Intervention: assessment of cognitive impairment
Description: Measure of Global Deficit Score

Intervention type: OTHER
Intervention: assessment of cognitive impairment
Description: Measure of Global Deficit Score
Study: NCT03613324

Intervention type: DIAGNOSTIC_TEST
Intervention: Pad test
Description: 20-minutes pad test and urodynamic study including uroflowmetry, filling cystometry and voiding cystometry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pad test
Description: 20-minutes pad test and urodynamic study including uroflowmetry, filling cystometry and voiding cystometry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pad test
Description: 20-minutes pad test and urodynamic study including uroflowmetry, filling cystometry and voiding cystometry.
Study: NCT02193659

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cereals
Description: The participants were randomly single blind controlled trial distributed into three groups: (1, n =38), (2, n =38), (3, n =37). For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet.
Study: NCT03286309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft robot hand system
Description: subjects will wear the soft robot hand system and receive 60 minutes (including preparation time) hand exercise.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: soft robot hand system
Description: subjects will wear the soft robot hand system and receive 60 minutes (including preparation time) hand exercise.
Study: NCT02670499

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPM
Description: Used to aid in recovery from TKR

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GAPFLEX
Description: Used to aid in the recovery of TKR
Study: NCT00025506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given orally
Study: NCT01838486

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bladder Thermal Distention
Description: Bladder Thermal Distention (BTD) is an approved procedure in Europe and Israel. Continuous irrigation of the bladder with warm saline with the PelvixTT system. The procedure will be performed on an outpatients basis. The procedure lasts 1 hour.
Study: NCT03567135

Intervention type: DRUG
Intervention: Apatinib
Description: These drugs are planned to inhibit the proliferation and metastasis of tumors.

Intervention type: DRUG
Intervention: Apatinib
Description: These drugs are planned to inhibit the proliferation and metastasis of tumors.

Intervention type: DRUG
Intervention: Temozolomide（TMZ）
Description: Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.

Intervention type: DRUG
Intervention: Temozolomide（TMZ）
Description: Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.

Intervention type: DRUG
Intervention: Temozolomide（TMZ）
Description: Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.
Study: NCT02860507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Study: NCT04128800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib S-1
Description: apatinib 250 mg PO qd; S-1 40 mg PO in the morning and 60 mg PO in the evening; 14 days in combination, 21 days in a cycle.
Study: NCT00818870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 20 mg capsule, orally, once daily (before breakfast) for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vecam
Description: 1 capsule, orally, once daily at bedtime for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vecam
Description: 1 capsule, orally, once daily at bedtime for 5 days.
Study: NCT01657877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium sodium phosphosilicate
Description: CSP high percentage weight by weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium sodium phosphosilicate
Description: CSP high percentage weight by weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium monoflurophosphate
Description: 500 to 1500 parts per million (ppm) of fluoride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monoflurophosphate
Description: 500 to 1500 parts per million (ppm) of fluoride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monoflurophosphate
Description: 500 to 1500 parts per million (ppm) of fluoride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No CSP and no fluoride
Study: NCT01089309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone orally, at a dose of 50 mg/day for 12 months
Study: NCT04191876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellth - Financial Incentives
Description: Patients who are willing to participate will be offered financial incentives for medication adherence through an app (Wellth) over 10 weeks.
Study: NCT03304756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP
Description: cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
Study: NCT01135082

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: valent pneumococcal conjugated vaccine
Description: Dosage: 0.5 ml per dose Administration: intramuscular injection Location: left deltoid area x 1 injection Frequency: depend on first dose of vaccination. If 2-6 months of age, vaccination at month 0, 2, and 4. If 7-23 months of age, vaccination at month 0 and 2. If 2-9 years of age, vaccination at month 0. If patient is HIV positive, vacciation months 0 and 2 if age is 2-9 years.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: valent pneumococcal conjugated vaccine
Description: Dosage: 0.5 ml per dose Administration: intramuscular injection Location: left deltoid area x 1 injection Frequency: depend on first dose of vaccination. If 2-6 months of age, vaccination at month 0, 2, and 4. If 7-23 months of age, vaccination at month 0 and 2. If 2-9 years of age, vaccination at month 0. If patient is HIV positive, vacciation months 0 and 2 if age is 2-9 years.
Study: NCT01648595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour after being diluted in 4 cc normal saline
Study: NCT00900783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valacyclovir
Description: 1 gram, three times a day for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FV-100
Description: 400 mg, once daily, for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FV-100
Description: 200 mg, once daily, for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir placebo
Description: three times a day, for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir placebo
Description: three times a day, for seven days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FV-100 placebo
Description: once daily, for seven days
Study: NCT00784147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibalizumab
Description: Ibalizumab 800 mg IV every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibalizumab
Description: Ibalizumab 2000 mg IV every 4 weeks
Study: NCT03131349

Intervention type: DIAGNOSTIC_TEST
Intervention: serum zinc and iron
Description: history ,examination,investigations

Intervention type: DIAGNOSTIC_TEST
Intervention: serum zinc and iron
Description: history ,examination,investigations
Study: NCT00480155

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Frozen FluMist®
Description: Monovalent vaccine is supplied in intranasal sprayers containing 0.5 mL.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01972945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginoscopy
Description: Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hysteroscopy
Description: Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
Study: NCT00329563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Up to 2 liter infusion of cold 4 degree C normal saline
Description: Patients randomized to field cooling will receive up to 2 liters of 4oC normal saline. Control patients will receive standard of care following resuscitation.
Study: NCT04718233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 25Mg Tablet
Description: Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo will be administered orally in patients with recurrent pregnancy loss